Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1381-1390

  Wei, Wei Tian ^a,b   Chen, Hui ^a   Ni, Zhong Lin ^a   Liu, Hai Bin ^a   Tong, Hong Fei ^a   Fan, Ling ^a   Liu, An ^a   Qiu, Mai Xuan ^a   Liu, Dian Lei ^a   Guo, Hong Chun ^a   Wang, Zhao Hong ^a   Lin, Sheng Zhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Apoptosis; Emodin; Gemcitabine; NF B; p Akt; SW1990 cells

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; EMODIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BODY WEIGHT; CASPASE 3; CELL LINE, TUMOR; CYTOCHROMES C; EMODIN; FEMALE; HUMANS; MICE; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RHEUM; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054801886     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1147     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Thomas A, Dajani K, Neoptolemos JP and Ghaneh P: Adjuvant therapy in pancreatic cancer. Dig Dis 28: 684-692, 2010.
3. Huguet F, Orthuon A, Touboul E, Marseguerra R and Mornex F: Pancreatic cancer. Cancer Radiother 14 (Suppl. 1): S94-S102, 2010.
4. Hilbig A and Oettle H: Adjuvant therapy of pancreatic cancer. Expert Rev Anticancer Ther 10: 485-491, 2010.
5. Shore S, Raraty MG, Ghaneh P and Neoptolemos JP: Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 18: 1049-1069, 2003. (Pubitemid 38021591)
6. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105, 1996. (Pubitemid 26026268)
7. Burris HA III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
8. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002. (Pubitemid 34831525)
9. Louvet C, Labianca R, Hammel P, et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
10. Heinemann V, Quietzsch D, Gieseler F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006. (Pubitemid 46630743)
11. Rocha Lima CM, Savarese D, Bruckner H, et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182-1191, 2002. (Pubitemid 34177423)
12. Kullmann F, Hollerbach S, Dollinger MM, et al.: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 100: 1032-1036, 2009.
13. Sato M, Maulik G, Bagchi D and Das DK: Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 32: 135-144, 2000. (Pubitemid 30056790)
14. Lin SZ, Chen KJ, Tong HF, Jing H, Li H and Zheng SS: Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats. Clin Exp Pharmacol Physiol 37: 790-794, 2010.
15. Liu A, Chen H, Wei W, et al.: Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep 26: 81-89, 2011.
16. Chen H, Wei W, Guo Y, et al.: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
17. Chen YC, Shen SC, Lee WR, Hsu FL, Lin HY, Ko CH and Tseng SW: Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64: 1713-1724, 2002. (Pubitemid 35351578)
18. Su YT, Chang HL, Shyue SK and Hsu SL: Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 70: 229-241, 2005.
19. Guo Q, Chen Y, Zhang B, Kang M, Xie Q and Wu Y: Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 77: 1674-1683, 2009.
20. Khanbolooki S, Nawrocki ST, Arumugam T, et al.: Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 5: 2251-2260, 2006. (Pubitemid 44530462)
21. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J and Hondermarck H: The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 24: 5482-5491, 2005. (Pubitemid 43080091)
22. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
23. Zong WX, Edelstein LC, Chen C, Bash J and Gelinas C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13: 382-387, 1999. (Pubitemid 29108753)
24. Cai J, Razzak A, Hering J, Saed A, Babcock TA, Helton S and Espat NJ: Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. JPEN J Parenter Enteral Nutr 32: 190-196, 2008. (Pubitemid 351464893)
25. Zheng HY, Hu JD, Zheng ZH, et al.: [Emodin induces leukemic HL-60 cells apoptosis probably by inhibiting Akt signal pathway]. Yao Xue Xue Bao 42: 1142-1146, 2007.
26. Olsen BB, Bjorling-Poulsen M and Guerra B: Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action. Int J Biochem Cell Biol 39: 227-237, 2007. (Pubitemid 44548449)
27. Liu D, Zhang Y, Dang C, Ma Q, Lee W and Chen W: siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol Rep 18: 673-677, 2007.
28. Yao J and Qian C: Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/ Akt-dependent pathway. Med Oncol 27: 1017-1022, 2010.
29. Zhang B, Shi ZL, Liu B, Yan XB, Feng J and Tao HM: Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs 21: 288-296, 2010.
30. Fahy BN, Schlieman M, Virudachalam S and Bold RJ: AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89: 391-397, 2003. (Pubitemid 36976331)
31. Lee SH, Ryu JK, Lee KY, et al.: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259: 39-49, 2008. (Pubitemid 350235089)
32. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T and Yanaga K: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res 29: 3173-3178, 2009.
33. Fahy BN, Schlieman MG, Virudachalam S and Bold RJ: Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599, 2004. (Pubitemid 38446534)
34. Li HL, Chen HL, Li H, et al.: Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 16: 41-47, 2005.
35. Kuo TC, Yang JS, Lin MW, et al.: Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330: 736-744, 2009.
36. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU and Brady JN: Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24: 6719-6728, 2005. (Pubitemid 41486802)
37. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H and Ungefroren H: Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109: 182-188, 2004. (Pubitemid 38240918)